

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Care of Patients with Follicular Lymphoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following statements best reflects the 5-year efficacy observed with tisagenlecleucel (tis-cel) for patients with high-risk relapsed/refractory (R/R) follicular lymphoma (FL) in the Phase II ELARA trial?
 - a. Tis-cel demonstrated a complete response (CR) rate of 69% but short duration of survival
 - b. Tis-cel demonstrated a CR rate of 24% and short duration of survival
 - c. Tis-cel demonstrated a CR rate of 69% and long-term survival
2. Approximately what proportion of patients with R/R FL who experienced disease response to second-line lisocabtagene maraleucel in the Phase II TRANSCEND FL trial achieved a CR?
 - a. 33%
 - b. 66%
 - c. 100%
3. Which of the following drug types best reflects the mechanism of action of odronextamab?
 - a. Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy
 - b. Anti-CD20/CD19 bispecific CAR T-cell therapy
 - c. Bispecific antibody
 - d. Trispecific antibody
4. Which of the following statements best characterizes efficacy outcomes observed with mosunetuzumab in longer-term follow-up from a pivotal Phase I/II study for patients with R/R FL?
 - a. A CR rate of 60%
 - b. A CR rate of 10%
 - c. A median progression-free survival (PFS) of 24 months
 - d. A median PFS of 15 months
 - e. Both a and c
 - f. Both b and d
5. Which of the following side effects was the most common treatment-related adverse event observed with golcadomide with or without rituximab in a Phase I/II study of patients with R/R FL?
 - a. Diarrhea
 - b. Neutropenia
 - c. Pruritus
 - d. Fever